Q1 2018 FINANCIAL RESULTS  
SALES WORLDWIDE

$7.4 billion  
+6.9% on organic basis*

**STRONG PERFORMANCE IN CORE BUSINESS SEGMENTS**

Sales on organic basis*

<table>
<thead>
<tr>
<th>Segment</th>
<th>Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health Care</td>
<td></td>
</tr>
<tr>
<td>Medical Devices</td>
<td>+9.4%</td>
</tr>
<tr>
<td>Established Pharmaceuticals</td>
<td>+6.8%</td>
</tr>
<tr>
<td>Nutrition</td>
<td>+4.7%</td>
</tr>
<tr>
<td>Diagnostics</td>
<td>+5.5%</td>
</tr>
</tbody>
</table>

**NEW APPROVALS**

U.S.
- Masters HP 15mm rotatable mechanical heart valve, first-ever FDA-approved heart valve for babies and toddlers
- MR-conditional labeling for Fortify Assura ICD and Quadra Assura and Quadra Assura MP CRT-D devices

EUROPE
- Alinity H-Series, a smaller, faster integrated hematology system
- Agreement with Primedic for next-generation drug-coated balloon

**NEW DEVELOPMENTS**

- Freestyle Libre System received CMS reimbursement in the U.S.
- Launched app for Freestyle Libre System in Europe for iPhone and Android
- MitraClip received national reimbursement in Japan
- Agreement with Surmodics for next-generation drug-coated balloon

**NEW DATA**

- New England Journal of Medicine data show HeartMate 3 LVAD demonstrated improved clinical outcomes over the most widely used LVAD in the world
- GUIDE-HF clinical trial initiated to evaluate improved survival and outcomes with the CardioMEMS monitor

**LIFE-CHANGING TECHNOLOGIES**

- Masters HP 15mm rotatable mechanical heart valve, first-ever FDA-approved heart valve for babies and toddlers
- MR-conditional labeling for Fortify Assura ICD and Quadra Assura and Quadra Assura MP CRT-D devices
- Alinity H-Series, a smaller, faster integrated hematology system
- Agreement with Primedic for next-generation drug-coated balloon

**FORWARD-LOOKING STATEMENTS**

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.